Frazier Life Sciences Management L.P. Raises Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Frazier Life Sciences Management L.P. lifted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 32.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,887,867 shares of the specialty pharmaceutical company's stock after purchasing an additional 1,200,000 shares during the period. KalVista Pharmaceuticals comprises approximately 1.7% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 16th biggest position. Frazier Life Sciences Management L.P. owned approximately 9.89% of KalVista Pharmaceuticals worth $41,400,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. SG Americas Securities LLC increased its holdings in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after buying an additional 1,319 shares during the last quarter. Legal & General Group Plc raised its holdings in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares during the period. JPMorgan Chase & Co. lifted its position in KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after purchasing an additional 1,670 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock valued at $150,000 after purchasing an additional 2,588 shares during the period.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the sale, the chief executive officer now owns 287,811 shares of the company's stock, valued at $3,445,097.67. This trade represents a 2.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider now directly owns 106,611 shares in the company, valued at $1,262,274.24. This trade represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,253 shares of company stock valued at $157,782. Company insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Stock Performance

KALV traded up $0.05 during trading on Monday, reaching $11.47. 368,958 shares of the company traded hands, compared to its average volume of 422,330. The company has a market cap of $570.24 million, a P/E ratio of -3.15 and a beta of 0.05. The firm has a fifty day simple moving average of $11.96 and a 200 day simple moving average of $10.44. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. Jones Trading reaffirmed a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).